Immunotherapy in Prostate Cancer

Current Urology Reports

Volumn 16, Issue 6, 2015, Pages 1-5

  Sobol, Ilya ^a   Thompson, R H ^a   Dong, Haidong ^a   Krco, Christopher ^a   Kwon, Eugene D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immunotherapy; Ipilimumab; Prostate cancer; PSA TRICOM

Indexed keywords

DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PROGRAMMED DEATH 1 LIGAND 1; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY; TAXOID;

CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG EFFICACY; HUMAN; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84928402716     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0509-7     Document Type: Review

References (15)

1. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089.
2. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer. Cancer. 2009;115:3670.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411. 3 Clinical trials revealing effectiveness of Sipuleucel-T.
4. Stewart F, Sheikh N, McNeel D, et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. 2010. Demonstration of biological parameters such as upregulation of CD54 cells among patients who received an overall survival benefit from treatment with Sipuleucel T.
5. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099. PSA-Tricom Phase II randomized trial results.
6. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30:251.
7. Carreno BM, Collins M. BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol. 2003;24:524. Basic science of T-cell response to tumor.
8. Khattri R, Auger JA, Griffin MD, et al. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol. 1999;162:5784. CTLA-4 knockout mice have been shown to survive for <1 month.
9. Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711. Overall improved survival with ipilimumab for patient with metastatic melanoma.
10. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700. Results of Ipilimumab phase III trial showing improved survival approaching statistical significance.
11. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793.
12. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261. PD-1 affect on T-cell.
13. Savage PA, Vosseller K, Kang C, et al. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science. 2008;319:215. Population of CD8 cytotoxic T-cells with activity against specific prostate adenocarcinoma proteins in mouse model.
14. Ahmadzadeh M et al. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–44. In the absence of PD-1, mouse model reveals that tumor growth is dramatically delayed.
15. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. N Engl J Med. 2013;369:134. Anti-PD-1 monoclonal antibody displayed an improvement in progression free survival for metastatic melanoma.